X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1323) 1323
Patent (34) 34
Publication (13) 13
Magazine Article (5) 5
Book Chapter (2) 2
Conference Proceeding (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (499) 499
gastroenterology & hepatology (437) 437
gastroenterology and hepatology (318) 318
male (297) 297
female (291) 291
adult (274) 274
crohn's disease (215) 215
middle aged (196) 196
inflammatory-bowel-disease (187) 187
ulcerative colitis (170) 170
inflammatory bowel disease (157) 157
crohns-disease (154) 154
infliximab (139) 139
ulcerative-colitis (120) 120
abridged index medicus (115) 115
treatment outcome (114) 114
crohn disease - drug therapy (113) 113
adolescent (98) 98
aged (97) 97
inflammatory bowel diseases (96) 96
risk factors (91) 91
young adult (84) 84
care and treatment (83) 83
therapy (74) 74
life sciences (62) 62
severity of illness index (61) 61
remission (58) 58
analysis (57) 57
antibodies, monoclonal - therapeutic use (56) 56
gastrointestinal diseases (55) 55
remission induction (55) 55
clinical trials (54) 54
colitis, ulcerative - drug therapy (53) 53
crohn disease - diagnosis (52) 52
immunosuppressive agents - therapeutic use (52) 52
maintenance therapy (52) 52
adalimumab (51) 51
follow-up studies (51) 51
organic chemistry (49) 49
double-blind method (48) 48
gastroenterology (48) 48
retrospective studies (48) 48
time factors (48) 48
azathioprine (47) 47
tumor necrosis factor-alpha - antagonists & inhibitors (47) 47
ibd (45) 45
risk (45) 45
colitis (44) 44
crohns disease (44) 44
gastrointestinal agents - therapeutic use (44) 44
child (43) 43
intestine (42) 42
management (42) 42
crohn disease - pathology (41) 41
patients (41) 41
animals (40) 40
inflammation (40) 40
c-reactive protein (39) 39
endoscopy (39) 39
medical research (39) 39
pharmacology & pharmacy (39) 39
crohn disease - genetics (38) 38
incidence (38) 38
quality of life (38) 38
efficacy (37) 37
inflammatory bowel diseases - drug therapy (37) 37
medical colleges (37) 37
prospective studies (37) 37
surgery (37) 37
anti-inflammatory agents - therapeutic use (36) 36
crohn disease - complications (36) 36
rheumatoid-arthritis (36) 36
crohn disease - immunology (34) 34
prognosis (34) 34
crohn’s disease (33) 33
diagnosis (33) 33
induction (33) 33
mice (33) 33
aged, 80 and over (32) 32
crohn disease - epidemiology (32) 32
intestinal mucosa - pathology (32) 32
medicine, experimental (32) 32
prevalence (32) 32
research (32) 32
cancer (31) 31
chemistry (31) 31
health aspects (31) 31
metallurgy (31) 31
recurrence (31) 31
antibodies, monoclonal - adverse effects (30) 30
colitis, ulcerative - diagnosis (30) 30
colonoscopy (30) 30
crohn disease - surgery (30) 30
epidemiology (30) 30
antibodies, monoclonal, humanized - therapeutic use (29) 29
chemical sciences (29) 29
crohn disease - therapy (29) 29
monoclonal antibodies (29) 29
human necessities (28) 28
hygiene (28) 28
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1321) 1321
French (76) 76
German (7) 7
Portuguese (2) 2
Danish (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10080, pp. 1756 - 1770
Journal Article
Gut, ISSN 0017-5749, 2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
INFLAMMATORY-BOWEL-DISEASE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | OPPORTUNISTIC INFECTIONS | FOLLOW-UP | RISK | EXPERIENCE | COHORT | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | MAINTENANCE THERAPY | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | 1506 | Inflammatory Bowel Disease
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9701, pp. 1617 - 1625
Journal Article